ReviewFrontiers in pharmacology2026
Hepatic lipid quantity and quality in type 2 diabetes mellitus.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of type 2 diabetes mellitus (T2DM) has been increasing worldwide. In the pathophysiology of metabolic diseases, including T2DM, both the quantity and quality of lipids that accumulate in the body have attracted significant research attention. Excess lipids accumulate in non-adipose tissues, such as the liver and skeletal muscles, leading to insulin resistance and an increased risk of developing T2DM. The liver is the central organ for glucose and lipid metabolism, and impaired hepatic regulatory mechanisms lead to hyperglycemia, insulin resistance, and hepatic lipid accumulation. Hepatic triglyceride (TG) accumulation contributes to the development of hepatic insulin resistance; however, the quantity of TGs alone is insufficient to explain the development of glucose and lipid metabolic dysfunctions. Thus, we focus on lipid quality, particularly fatty acids. In addition to TGs, phospholipids store fatty acids, which vary in carbon chain length, number of double bonds, and position of double bonds (such as ω3 and ω6), resulting in lipid diversity. Changes in the fatty acid chains of phospholipids are also strongly associated with glucose and lipid metabolism. In this mini review, we discuss the involvement of hepatic lipid quantity and quality in T2DM, with the aim of contributing to the development of novel T2DM therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.